Welcome to our searchable resource and literature collection on safer supply and related topics.
Found a broken link? Links do move around, so if you find one here that's broken, please let us know through the Contact form.
Resources
Commentary | 2023
Substitution/OAT, About prescribers, Clinical guidance, Policy/Regulatory, Hesitancy of prescribers
The purpose of this systematic scoping review is to: 1) review published curricula on harm reduction for substance use implemented by undergraduate (UME) and graduate medical education (GME) in the
Scoping review | 2023
Harm reduction, About prescribers, Clinical guidance
Commentary | 2023
About prescribers, Clinical guidance
Guidelines | 2023
Stimulants, About prescribers, Clinical guidance
Archived webinar | 2023
Clinical guidance, About prescribers
Case study | 2023
Hospitals, Withdrawal, About prescribers, Clinical guidance
Guidelines | 2023
About prescribers, Withdrawal, Clinical guidance
Infographic | 2023
Overdose, Clinical guidance, Harm reduction
Commentary | 2023
Clinical guidance, Harm reduction, Wrap-around services, About PWUD
Commentary | 2023
Clinical guidance, About prescribers
Guidelines | 2023
Clinical guidance, Harm reduction, Safer supply, About prescribers
Guidelines | 2023
Clinical guidance, Harm reduction, Safer supply, About prescribers
Commentaire | 2023
l'approvisionnement plus sécuritaire, les stimulants, à propos des prescripteurs, la politique / le cadre de réglementation, les guides de pratique clinique
The purpose of this guidance is to provide policy recommendations for territorial, provincial and federal takehome naloxone (THN) programs, using evidence from scientific and grey literature and co
Guidelines | 2023
Policy/Regulatory, Harm reduction, Clinical guidance, Overdose
Cours de formation | 2023
la douleur chronique, à propos des prescripteurs, les guides de pratique clinique
Training | 2023
Chronic pain, About prescribers, Clinical guidance
We discuss major domains of xylazine’s harm, current knowledge deficits, clinical and harm reduction strategies for minimizing harm, and xylazine’s public health and policy context.
Lit review | 2023
About prescribers, Illegal drugs, Harm reduction, Clinical guidance
Commentary | 2023
Overdose, Illegal drugs, Clinical guidance
Guide | 2023
à propos des pharmaciens, à propos des prescripteurs, les guides de pratique clinique, la politique / le cadre de réglementation, l'hésitation des prescripteurs, l'approvisionnement plus sécuritaire
